Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Símbolo de cotizaciónXGN
Nombre de la empresaExagen Inc
Fecha de salida a bolsaSep 19, 2019
Director ejecutivoMr. John Aballi
Número de empleados203
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 19
Dirección1261 Liberty Way
CiudadVISTA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92081
Teléfono17605601501
Sitio Webhttps://exagen.com/
Símbolo de cotizaciónXGN
Fecha de salida a bolsaSep 19, 2019
Director ejecutivoMr. John Aballi
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos